AbbVie
AbbVie Inc. (NYSE: ABBV) is a global, diversified research-based biopharmaceutical company headquartered in the United States. The company was incorporated in Delaware on April 10, 2012, and became an independent, publicly-traded entity on January 1, 2013, following its distribution by Abbott Laboratories to Abbott's… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What AbbVie does
In the company’s own words
AbbVie Inc. (NYSE: ABBV) is a global, diversified research-based biopharmaceutical company headquartered in the United States. The company was incorporated in Delaware on April 10, 2012, and became an independent, publicly-traded entity on January 1, 2013, following its distribution by Abbott Laboratories to Abbott's shareholders. AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. The company website is www.abbvie.com.
AbbVie maintains a comprehensive product portfolio with leadership positions across four primary therapeutic areas: immunology, neuroscience, oncology, and aesthetics. The immunology portfolio includes blockbuster products such as Skyrizi, a selective IL-23 inhibitor approved for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; Rinvoq, an oral JAK inhibitor for rheumatoid arthritis and multiple inflammatory conditions; and Humira, a TNF-blocking biologic therapy. The neuroscience division offers Vraylar for schizophrenia and bipolar disorder, Botox Therapeutic for chronic migraine and overactive bladder, and migraine prevention treatments Ubrelvy and Qulipta. The oncology portfolio includes Imbruvica for blood cancers, Venclexta for leukemia and lymphoma, and Elahere for ovarian cancer. AbbVie's aesthetics segment features market-leading products including Botox Cosmetic, the Juvederm Collection of dermal fillers, and CoolSculpting body contouring technology. The company also markets eye care products, hepatitis C treatments, and other specialized therapies.
AbbVie distributes its products globally through a combination of dedicated commercial resources, regional teams, and distributorships. In the United States, three major wholesale distributors handle substantially all pharmaceutical product sales. The company operates integrated discovery and development teams comprising chemists, biologists, physicians, and pharmacologists, and supplements internal research efforts through partnerships with biotechnology companies, academic institutions, and strategic acquisitions. AbbVie's intellectual property portfolio includes thousands of patent families, with key patents covering risankizumab and upadacitinib expected to expire in 2033, providing substantial competitive protection for core products.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NORTH CHICAGO, IL
- Fiscal year end
- December
- CIK
- 1551152
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns AbbVie — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in AbbVie · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · AbbVie’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
AbbVie’s bonds, as funds hold them
Funds report holding 39 issues of AbbVie’s debt, $10.56B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.47%, maturing 2026 to 2066.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do AbbVie and its peers compare on margins and cash generation over ten years?”
- “Where did five years of AbbVie's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in AbbVie's last four quarterly filings that the numbers alone won't show?”